Cenra（1701）株式概要センラ・インクは、ヒトおよび動物用のジェネリック医薬品およびヘルスケア製品の研究開発、製造、販売を行っている。 詳細1701 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績1/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より48.9%で取引されている リスク分析過去5年間で収益は年間3.3%減少しました。 すべてのリスクチェックを見る1701 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$21.1538.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture010b2016201920222025202620282031Revenue NT$10.0bEarnings NT$399.5mAdvancedSet Fair ValueView all narrativesCenra Inc. 競合他社Savior LifetecSymbol: TPEX:4167Market cap: NT$5.9bSinphar PharmaceuticalLtdSymbol: TWSE:1734Market cap: NT$6.1bFormosa LaboratoriesSymbol: TWSE:4746Market cap: NT$6.1bPanion & Bf BiotechSymbol: TWSE:1760Market cap: NT$5.1b価格と性能株価の高値、安値、推移の概要Cenra過去の株価現在の株価NT$21.1552週高値NT$26.4052週安値NT$20.20ベータ01ヶ月の変化3.42%3ヶ月変化-4.94%1年変化-8.84%3年間の変化-9.23%5年間の変化13.40%IPOからの変化-38.58%最新ニュースお知らせ • Mar 06Cenra Inc., Annual General Meeting, May 26, 2026Cenra Inc., Annual General Meeting, May 26, 2026. Location: 4 floor no,2, hsu chou rd., taipei city Taiwanお知らせ • Mar 07+ 1 more updateCenra Inc., Annual General Meeting, May 27, 2025Cenra Inc., Annual General Meeting, May 27, 2025. Location: 4 floor no,2, hsu chou rd., taipei city Taiwanお知らせ • Feb 27Cenra Inc. to Report Fiscal Year 2024 Results on Mar 06, 2025Cenra Inc. announced that they will report fiscal year 2024 results on Mar 06, 2025お知らせ • Oct 30+ 1 more updateCenra Inc. Approves Salary and Remuneration Committee AppointmentsCenra Inc. announced the company’s board of directors has approved the appointment of members of the first salary and remuneration committee. Name of the new position holder: Chen, Hung-Shou; Chou, Ta Jen; Leu, Chia-Hwel. Resume of the new position holder: Chen, Hung-Shou/Chairman of OneAD Inc.; Chou, Ta Jen/CTC Capital Inc, Chairman; Leu, Chia-Hwel/Chairman of Hong Qun Investment Co., LTD. Effective date of the new member is October 29, 2024.お知らせ • Oct 09Cenra Inc.(UNQ:1701) dropped from Taiwan TAIEX IndexCenra Inc. has been dropped from the Taiwan TAIEX IndexReported Earnings • Aug 16Second quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.18 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.27 (up from NT$0.18 in 2Q 2023). Revenue: NT$2.22b (up 5.2% from 2Q 2023). Net income: NT$80.3m (up 51% from 2Q 2023). Profit margin: 3.6% (up from 2.5% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.最新情報をもっと見るRecent updatesお知らせ • Mar 06Cenra Inc., Annual General Meeting, May 26, 2026Cenra Inc., Annual General Meeting, May 26, 2026. Location: 4 floor no,2, hsu chou rd., taipei city Taiwanお知らせ • Mar 07+ 1 more updateCenra Inc., Annual General Meeting, May 27, 2025Cenra Inc., Annual General Meeting, May 27, 2025. Location: 4 floor no,2, hsu chou rd., taipei city Taiwanお知らせ • Feb 27Cenra Inc. to Report Fiscal Year 2024 Results on Mar 06, 2025Cenra Inc. announced that they will report fiscal year 2024 results on Mar 06, 2025お知らせ • Oct 30+ 1 more updateCenra Inc. Approves Salary and Remuneration Committee AppointmentsCenra Inc. announced the company’s board of directors has approved the appointment of members of the first salary and remuneration committee. Name of the new position holder: Chen, Hung-Shou; Chou, Ta Jen; Leu, Chia-Hwel. Resume of the new position holder: Chen, Hung-Shou/Chairman of OneAD Inc.; Chou, Ta Jen/CTC Capital Inc, Chairman; Leu, Chia-Hwel/Chairman of Hong Qun Investment Co., LTD. Effective date of the new member is October 29, 2024.お知らせ • Oct 09Cenra Inc.(UNQ:1701) dropped from Taiwan TAIEX IndexCenra Inc. has been dropped from the Taiwan TAIEX IndexReported Earnings • Aug 16Second quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.18 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.27 (up from NT$0.18 in 2Q 2023). Revenue: NT$2.22b (up 5.2% from 2Q 2023). Net income: NT$80.3m (up 51% from 2Q 2023). Profit margin: 3.6% (up from 2.5% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • Aug 05Now 25% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.3% to NT$20.40. The fair value is estimated to be NT$27.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Earnings per share has declined by 15%.お知らせ • Jul 30China Chemical & Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024China Chemical & Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Aug 06, 2024Upcoming Dividend • Jul 20Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 25 July 2024. Payment date: 20 August 2024. Payout ratio is a comfortable 45% and the cash payout ratio is 93%. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (4.3%). In line with average of industry peers (2.0%).分析記事 • Jul 12China Chemical & Pharmaceutical's (TWSE:1701) Dividend Will Be Reduced To NT$0.50China Chemical & Pharmaceutical Co., Ltd. ( TWSE:1701 ) has announced that on 20th of August, it will be paying a...Declared Dividend • Jul 06Dividend reduced to NT$0.50Dividend of NT$0.50 is 38% lower than last year. Ex-date: 25th July 2024 Payment date: 20th August 2024 Dividend yield will be 2.2%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (45% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.お知らせ • May 29China Chemical & Pharmaceutical Co., Ltd. Announces Cenra Inc Appoints Wang Hsieh, I-Chen as Chairman of the Board of Directors, Effective September 2, 2024China Chemical & Pharmaceutical Co., Ltd. announced Cenra Inc. to appoint the Chairman of the Board of Directors. Name of the new position holder: Chunghwa Chemical Synthesis & Biotech Co., Ltd. Representative: Wang Hsieh, I-Chen. Resume of the new position holder: Chunghwa Chemical Synthesis & Biotech Co., Ltd. Representative: Wang Hsieh, I-Chen/Chairman of the company. Reason for the change: CCPC held a regular shareholders--meeting on May 28, 2024 (also deemed to be a shareholder of Cenra Inc. founders-- meeting) to complete the election of the first directors and supervisors, led by Cenra Inc. Ms. Wang Hsieh, I-Chen, the director with the highest number of votes in the first term, convened the first board of directors, and the meeting was approved by Cenra Inc. The board of directors of the company unanimously elected Director Wang Hsieh, I-Chen as chairman of the board. The exercise of powers and term of office of the new chairman of the board of directors will start from the time when the election results are confirmed until the results of the next director election are confirmed. Effective date of appointment is September 2, 2024.Reported Earnings • May 18First quarter 2024 earnings released: EPS: NT$0.36 (vs NT$0.34 in 1Q 2023)First quarter 2024 results: EPS: NT$0.36 (up from NT$0.34 in 1Q 2023). Revenue: NT$2.28b (up 8.9% from 1Q 2023). Net income: NT$105.8m (up 5.7% from 1Q 2023). Profit margin: 4.6% (down from 4.8% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • May 02China Chemical & Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 09, 2024China Chemical & Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on May 09, 2024Reported Earnings • Apr 02Full year 2023 earnings released: EPS: NT$1.08 (vs NT$1.61 in FY 2022)Full year 2023 results: EPS: NT$1.08 (down from NT$1.61 in FY 2022). Revenue: NT$8.57b (up 1.4% from FY 2022). Net income: NT$322.3m (down 33% from FY 2022). Profit margin: 3.8% (down from 5.6% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has remained flat, which means it is well ahead of earnings.お知らせ • Mar 12China Chemical & Pharmaceutical Co., Ltd. Proposes Dividend Distribution for the Year Ended December 31, 2023China Chemical & Pharmaceutical Co., Ltd. proposed appropriations of earnings in cash dividends to shareholders of TWD 0.5 per share for the year ended December 31, 2023.お知らせ • Feb 02China Chemical & Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024China Chemical & Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024. Location: No. 2, Xuzhou Road, Zhongzheng District Taipei Taiwan Agenda: To consider the 2023 Business Report; to consider audit committees review report on the 2023 financial statements; to consider Distribution of employees and directors compensation in 2023; to consider Other report items; and to consider other matters.New Risk • Aug 12New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.5% Last year net profit margin: 6.6% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: NT$0.18 (vs NT$0.52 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.18 (down from NT$0.52 in 2Q 2022). Revenue: NT$2.11b (up 1.3% from 2Q 2022). Net income: NT$53.0m (down 66% from 2Q 2022). Profit margin: 2.5% (down from 7.5% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Upcoming Dividend • Jul 18Upcoming dividend of NT$0.80 per share at 3.2% yieldEligible shareholders must have bought the stock before 25 July 2023. Payment date: 22 August 2023. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 3.2%. Lower than top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.5%).お知らせ • Jun 30China Chemical & Pharmaceutical Co., Ltd. Approves Cash Dividend, Payable on August 22, 2023China Chemical & Pharmaceutical Co., Ltd. at its shareholders meeting held on June 29, 2023, approved cash dividends to shareholders TWD 238,464,864 (TWD 0.8 per share). Ex-rights (ex-dividend) trading date is July 25, 2023. Ex-rights (ex-dividend) record date is July 31, 2023. Cash Dividend Payment Date is August 22, 2023.Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improved over the past weekAfter last week's 20% share price gain to NT$34.15, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 99% over the past three years.Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$25.30, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 49% over the past three years.Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Director Hilo Chen is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: NT$0.43 (vs NT$0.43 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.43 (down from NT$0.43 in 3Q 2021). Revenue: NT$2.08b (up 8.7% from 3Q 2021). Net income: NT$126.8m (down 1.6% from 3Q 2021). Profit margin: 6.1% (down from 6.7% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year.Reported Earnings • Aug 13Second quarter 2022 earnings released: EPS: NT$0.52 (vs NT$0.35 in 2Q 2021)Second quarter 2022 results: EPS: NT$0.52 (up from NT$0.35 in 2Q 2021). Revenue: NT$2.08b (up 2.2% from 2Q 2021). Net income: NT$155.3m (up 48% from 2Q 2021). Profit margin: 7.5% (up from 5.2% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 5% per year.Upcoming Dividend • Jul 18Upcoming dividend of NT$0.90 per shareEligible shareholders must have bought the stock before 25 July 2022. Payment date: 19 August 2022. Payout ratio is a comfortable 56% but the company is paying out more than the cash it is generating. Trailing yield: 4.2%. Lower than top quartile of Taiwanese dividend payers (6.8%). Higher than average of industry peers (2.9%).お知らせ • Jun 29China Chemical & Pharmaceutical Co., Ltd. Announces Cash Dividends to Shareholders, Payable on August 19, 2022China Chemical & Pharmaceutical Co., Ltd. announced Cash dividends to shareholders TWD 268,272,972 (TWD 0.9 per share). Ex-rights (ex-dividend) trading date is July 25, 2022. Ex-rights (ex-dividend) record date is July 31, 2022. Cash Dividend Payment Date is August 19, 2022.Board Change • Jun 04High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Director Hilo Chen is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 27+ 2 more updatesChina Chemical & Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021China Chemical & Pharmaceutical Co., Ltd. at its 2022 annual shareholders meeting held on May 26, 2022, approved cash dividend was TWD 268,272,972 (TWD 0.9 per share) for 2021.Reported Earnings • May 16First quarter 2022 earnings released: EPS: NT$0.30 (vs NT$0.43 in 1Q 2021)First quarter 2022 results: EPS: NT$0.30 (down from NT$0.43 in 1Q 2021). Revenue: NT$1.98b (flat on 1Q 2021). Net income: NT$88.5m (down 31% from 1Q 2021). Profit margin: 4.5% (down from 6.5% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Yen Pong Jou was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improved over the past weekAfter last week's 23% share price gain to NT$27.75, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 22x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 65% over the past three years.Reported Earnings • Apr 01Full year 2021 earnings released: EPS: NT$1.74 (vs NT$1.88 in FY 2020)Full year 2021 results: EPS: NT$1.74 (down from NT$1.88 in FY 2020). Revenue: NT$7.95b (down 2.8% from FY 2020). Net income: NT$517.5m (down 7.2% from FY 2020). Profit margin: 6.5% (down from 6.8% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 10China Chemical & Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year Ended December 31, 2021China Chemical & Pharmaceutical Co., Ltd. announced appropriations of earnings in cash dividends to shareholders is TWD 0.9 for the period ended December 31, 2021.Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS NT$0.43 (vs NT$0.40 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: NT$1.91b (down 5.4% from 3Q 2020). Net income: NT$128.8m (up 9.7% from 3Q 2020). Profit margin: 6.7% (up from 5.8% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 13Second quarter 2021 earnings released: EPS NT$0.35 (vs NT$0.78 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$2.04b (up 6.4% from 2Q 2020). Net income: NT$105.1m (down 55% from 2Q 2020). Profit margin: 5.2% (down from 12% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Jul 16Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 23 July 2021. Payment date: 20 August 2021. Trailing yield: 4.0%. Lower than top quartile of Taiwanese dividend payers (5.0%). Higher than average of industry peers (2.2%).Reported Earnings • May 15First quarter 2021 earnings released: EPS NT$0.43 (vs NT$0.38 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: NT$1.99b (down 4.5% from 1Q 2020). Net income: NT$128.6m (up 15% from 1Q 2020). Profit margin: 6.5% (up from 5.4% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.分析記事 • Apr 25Here's Why We Think China Chemical & Pharmaceutical (TPE:1701) Is Well Worth WatchingLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...分析記事 • Apr 07We Think China Chemical & Pharmaceutical (TPE:1701) Can Stay On Top Of Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Mar 31Full year 2020 earnings released: EPS NT$1.88 (vs NT$1.29 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$8.18b (up 2.7% from FY 2019). Net income: NT$557.4m (up 45% from FY 2019). Profit margin: 6.8% (up from 4.8% in FY 2019). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 17The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 34% And Shareholders Are Holding OnOn average, over time, stock markets tend to rise higher. This makes investing attractive. But not every stock you buy...分析記事 • Feb 24China Chemical & Pharmaceutical Co., Ltd.'s (TPE:1701) Stock Has Shown A Decent Performance: Have Financials A Role To Play?Most readers would already know that China Chemical & Pharmaceutical's (TPE:1701) stock increased by 2.7% over the past...分析記事 • Jan 27Is China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) A Good Fit For Your Dividend Portfolio?Is China Chemical & Pharmaceutical Co., Ltd. ( TPE:1701 ) a good dividend stock? How can we tell? Dividend paying...Is New 90 Day High Low • Jan 15New 90-day low: NT$22.50The company is down 1.0% from its price of NT$22.65 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 19% over the same period.分析記事 • Jan 06Does China Chemical & Pharmaceutical (TPE:1701) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Dec 23New 90-day high: NT$23.80The company is up 1.0% from its price of NT$23.50 on 24 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 12% over the same period.分析記事 • Dec 16The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 22% And Shareholders Are Holding OnBuying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are...分析記事 • Nov 26China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?With its stock down 3.7% over the past three months, it is easy to disregard China Chemical & Pharmaceutical...Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS NT$0.39The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$2.02b (up 2.8% from 3Q 2019). Net income: NT$117.5m (up 20% from 3Q 2019). Profit margin: 5.8% (up from 5.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 10China Chemical & Pharmaceutical Co., Ltd. Announces Chow,Dah-Jen as Member of Compensation CommitteeChina Chemical & Pharmaceutical Co., Ltd. announced new appointment Member of Compensation Committee, effective November 9, 2020. Name and resume of the new position holder: CHOW,DAH-JEN /AmTRAN Technology’s Independent Director.お知らせ • Nov 06+ 1 more updateChina Chemical & Pharmaceutical Co., Ltd. Announces Executive ChangesChina Chemical & Pharmaceutical Co., Ltd. announced the Name and resume of the previous position holder: Wang, Hsun-Sheng/CCPC of chairperson. Name and resume of the new position holder: Wang Hsieh Yi-Chen/Ma Jia De Enterprise Co., Ltd. of chairperson. These Changes are effective from November 05, 2020.株主還元1701TW PharmaceuticalsTW 市場7D0%-3.2%-4.3%1Y-8.8%-16.0%95.6%株主還元を見る業界別リターン: 1701過去 1 年間で-16 % の収益を上げたTW Pharmaceuticals業界を下回りました。リターン対市場: 1701は、過去 1 年間で95.6 % のリターンを上げたTW市場を下回りました。価格変動Is 1701's price volatile compared to industry and market?1701 volatility1701 Average Weekly Movement2.9%Pharmaceuticals Industry Average Movement5.1%Market Average Movement6.5%10% most volatile stocks in TW Market12.1%10% least volatile stocks in TW Market2.6%安定した株価: 1701 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 1701の 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2024n/aChih-Yung Wuwww.cenra.com株式会社センラは、ヒトおよび動物用のジェネリック医薬品およびヘルスケア製品の研究開発、製造、販売を行っている。医薬品原薬、ヒト用ジェネリック医薬品、一般用医薬品、疾病予防・セルフケア用ヘルスケア製品、ホームケア・化粧品、動物用ヘルスケア製品を提供。また、研究開発、製造委託、国際事業、医薬品ブランドの販売・流通、シニアケアサービスも行っている。センラ・インクは1952年に設立され、本社は台湾の台北市にある。もっと見るCenra Inc. 基礎のまとめCenra の収益と売上を時価総額と比較するとどうか。1701 基礎統計学時価総額NT$6.01b収益（TTM）NT$355.20m売上高(TTM)NT$8.87b16.2xPER（株価収益率0.6xP/Sレシオ1701 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1701 損益計算書（TTM）収益NT$8.87b売上原価NT$5.61b売上総利益NT$3.26bその他の費用NT$2.91b収益NT$355.20m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）2.38グロス・マージン36.79%純利益率4.00%有利子負債／自己資本比率36.9%1701 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/09/04 08:21終値2024/09/02 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cenra Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Wei Zheng KitCitigroup IncYuan LuKGI Securities Co. Ltd.Evana ChenMasterlink Securities Investment Advisory1 その他のアナリストを表示
お知らせ • Mar 06Cenra Inc., Annual General Meeting, May 26, 2026Cenra Inc., Annual General Meeting, May 26, 2026. Location: 4 floor no,2, hsu chou rd., taipei city Taiwan
お知らせ • Mar 07+ 1 more updateCenra Inc., Annual General Meeting, May 27, 2025Cenra Inc., Annual General Meeting, May 27, 2025. Location: 4 floor no,2, hsu chou rd., taipei city Taiwan
お知らせ • Feb 27Cenra Inc. to Report Fiscal Year 2024 Results on Mar 06, 2025Cenra Inc. announced that they will report fiscal year 2024 results on Mar 06, 2025
お知らせ • Oct 30+ 1 more updateCenra Inc. Approves Salary and Remuneration Committee AppointmentsCenra Inc. announced the company’s board of directors has approved the appointment of members of the first salary and remuneration committee. Name of the new position holder: Chen, Hung-Shou; Chou, Ta Jen; Leu, Chia-Hwel. Resume of the new position holder: Chen, Hung-Shou/Chairman of OneAD Inc.; Chou, Ta Jen/CTC Capital Inc, Chairman; Leu, Chia-Hwel/Chairman of Hong Qun Investment Co., LTD. Effective date of the new member is October 29, 2024.
お知らせ • Oct 09Cenra Inc.(UNQ:1701) dropped from Taiwan TAIEX IndexCenra Inc. has been dropped from the Taiwan TAIEX Index
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.18 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.27 (up from NT$0.18 in 2Q 2023). Revenue: NT$2.22b (up 5.2% from 2Q 2023). Net income: NT$80.3m (up 51% from 2Q 2023). Profit margin: 3.6% (up from 2.5% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 06Cenra Inc., Annual General Meeting, May 26, 2026Cenra Inc., Annual General Meeting, May 26, 2026. Location: 4 floor no,2, hsu chou rd., taipei city Taiwan
お知らせ • Mar 07+ 1 more updateCenra Inc., Annual General Meeting, May 27, 2025Cenra Inc., Annual General Meeting, May 27, 2025. Location: 4 floor no,2, hsu chou rd., taipei city Taiwan
お知らせ • Feb 27Cenra Inc. to Report Fiscal Year 2024 Results on Mar 06, 2025Cenra Inc. announced that they will report fiscal year 2024 results on Mar 06, 2025
お知らせ • Oct 30+ 1 more updateCenra Inc. Approves Salary and Remuneration Committee AppointmentsCenra Inc. announced the company’s board of directors has approved the appointment of members of the first salary and remuneration committee. Name of the new position holder: Chen, Hung-Shou; Chou, Ta Jen; Leu, Chia-Hwel. Resume of the new position holder: Chen, Hung-Shou/Chairman of OneAD Inc.; Chou, Ta Jen/CTC Capital Inc, Chairman; Leu, Chia-Hwel/Chairman of Hong Qun Investment Co., LTD. Effective date of the new member is October 29, 2024.
お知らせ • Oct 09Cenra Inc.(UNQ:1701) dropped from Taiwan TAIEX IndexCenra Inc. has been dropped from the Taiwan TAIEX Index
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: NT$0.27 (vs NT$0.18 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.27 (up from NT$0.18 in 2Q 2023). Revenue: NT$2.22b (up 5.2% from 2Q 2023). Net income: NT$80.3m (up 51% from 2Q 2023). Profit margin: 3.6% (up from 2.5% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • Aug 05Now 25% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.3% to NT$20.40. The fair value is estimated to be NT$27.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Earnings per share has declined by 15%.
お知らせ • Jul 30China Chemical & Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 06, 2024China Chemical & Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Aug 06, 2024
Upcoming Dividend • Jul 20Upcoming dividend of NT$0.50 per shareEligible shareholders must have bought the stock before 25 July 2024. Payment date: 20 August 2024. Payout ratio is a comfortable 45% and the cash payout ratio is 93%. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (4.3%). In line with average of industry peers (2.0%).
分析記事 • Jul 12China Chemical & Pharmaceutical's (TWSE:1701) Dividend Will Be Reduced To NT$0.50China Chemical & Pharmaceutical Co., Ltd. ( TWSE:1701 ) has announced that on 20th of August, it will be paying a...
Declared Dividend • Jul 06Dividend reduced to NT$0.50Dividend of NT$0.50 is 38% lower than last year. Ex-date: 25th July 2024 Payment date: 20th August 2024 Dividend yield will be 2.2%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is covered by both earnings (45% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has remained flat since 10 years ago. However, payments have been volatile during that time. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
お知らせ • May 29China Chemical & Pharmaceutical Co., Ltd. Announces Cenra Inc Appoints Wang Hsieh, I-Chen as Chairman of the Board of Directors, Effective September 2, 2024China Chemical & Pharmaceutical Co., Ltd. announced Cenra Inc. to appoint the Chairman of the Board of Directors. Name of the new position holder: Chunghwa Chemical Synthesis & Biotech Co., Ltd. Representative: Wang Hsieh, I-Chen. Resume of the new position holder: Chunghwa Chemical Synthesis & Biotech Co., Ltd. Representative: Wang Hsieh, I-Chen/Chairman of the company. Reason for the change: CCPC held a regular shareholders--meeting on May 28, 2024 (also deemed to be a shareholder of Cenra Inc. founders-- meeting) to complete the election of the first directors and supervisors, led by Cenra Inc. Ms. Wang Hsieh, I-Chen, the director with the highest number of votes in the first term, convened the first board of directors, and the meeting was approved by Cenra Inc. The board of directors of the company unanimously elected Director Wang Hsieh, I-Chen as chairman of the board. The exercise of powers and term of office of the new chairman of the board of directors will start from the time when the election results are confirmed until the results of the next director election are confirmed. Effective date of appointment is September 2, 2024.
Reported Earnings • May 18First quarter 2024 earnings released: EPS: NT$0.36 (vs NT$0.34 in 1Q 2023)First quarter 2024 results: EPS: NT$0.36 (up from NT$0.34 in 1Q 2023). Revenue: NT$2.28b (up 8.9% from 1Q 2023). Net income: NT$105.8m (up 5.7% from 1Q 2023). Profit margin: 4.6% (down from 4.8% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • May 02China Chemical & Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 09, 2024China Chemical & Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on May 09, 2024
Reported Earnings • Apr 02Full year 2023 earnings released: EPS: NT$1.08 (vs NT$1.61 in FY 2022)Full year 2023 results: EPS: NT$1.08 (down from NT$1.61 in FY 2022). Revenue: NT$8.57b (up 1.4% from FY 2022). Net income: NT$322.3m (down 33% from FY 2022). Profit margin: 3.8% (down from 5.6% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
お知らせ • Mar 12China Chemical & Pharmaceutical Co., Ltd. Proposes Dividend Distribution for the Year Ended December 31, 2023China Chemical & Pharmaceutical Co., Ltd. proposed appropriations of earnings in cash dividends to shareholders of TWD 0.5 per share for the year ended December 31, 2023.
お知らせ • Feb 02China Chemical & Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024China Chemical & Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024. Location: No. 2, Xuzhou Road, Zhongzheng District Taipei Taiwan Agenda: To consider the 2023 Business Report; to consider audit committees review report on the 2023 financial statements; to consider Distribution of employees and directors compensation in 2023; to consider Other report items; and to consider other matters.
New Risk • Aug 12New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.5% Last year net profit margin: 6.6% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 12Second quarter 2023 earnings released: EPS: NT$0.18 (vs NT$0.52 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.18 (down from NT$0.52 in 2Q 2022). Revenue: NT$2.11b (up 1.3% from 2Q 2022). Net income: NT$53.0m (down 66% from 2Q 2022). Profit margin: 2.5% (down from 7.5% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Upcoming Dividend • Jul 18Upcoming dividend of NT$0.80 per share at 3.2% yieldEligible shareholders must have bought the stock before 25 July 2023. Payment date: 22 August 2023. Payout ratio is a comfortable 49% but the company is paying out more than the cash it is generating. Trailing yield: 3.2%. Lower than top quartile of Taiwanese dividend payers (5.4%). Higher than average of industry peers (1.5%).
お知らせ • Jun 30China Chemical & Pharmaceutical Co., Ltd. Approves Cash Dividend, Payable on August 22, 2023China Chemical & Pharmaceutical Co., Ltd. at its shareholders meeting held on June 29, 2023, approved cash dividends to shareholders TWD 238,464,864 (TWD 0.8 per share). Ex-rights (ex-dividend) trading date is July 25, 2023. Ex-rights (ex-dividend) record date is July 31, 2023. Cash Dividend Payment Date is August 22, 2023.
Valuation Update With 7 Day Price Move • Dec 27Investor sentiment improved over the past weekAfter last week's 20% share price gain to NT$34.15, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 99% over the past three years.
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$25.30, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 49% over the past three years.
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Director Hilo Chen is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Third quarter 2022 earnings released: EPS: NT$0.43 (vs NT$0.43 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.43 (down from NT$0.43 in 3Q 2021). Revenue: NT$2.08b (up 8.7% from 3Q 2021). Net income: NT$126.8m (down 1.6% from 3Q 2021). Profit margin: 6.1% (down from 6.7% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 3% per year.
Reported Earnings • Aug 13Second quarter 2022 earnings released: EPS: NT$0.52 (vs NT$0.35 in 2Q 2021)Second quarter 2022 results: EPS: NT$0.52 (up from NT$0.35 in 2Q 2021). Revenue: NT$2.08b (up 2.2% from 2Q 2021). Net income: NT$155.3m (up 48% from 2Q 2021). Profit margin: 7.5% (up from 5.2% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 5% per year.
Upcoming Dividend • Jul 18Upcoming dividend of NT$0.90 per shareEligible shareholders must have bought the stock before 25 July 2022. Payment date: 19 August 2022. Payout ratio is a comfortable 56% but the company is paying out more than the cash it is generating. Trailing yield: 4.2%. Lower than top quartile of Taiwanese dividend payers (6.8%). Higher than average of industry peers (2.9%).
お知らせ • Jun 29China Chemical & Pharmaceutical Co., Ltd. Announces Cash Dividends to Shareholders, Payable on August 19, 2022China Chemical & Pharmaceutical Co., Ltd. announced Cash dividends to shareholders TWD 268,272,972 (TWD 0.9 per share). Ex-rights (ex-dividend) trading date is July 25, 2022. Ex-rights (ex-dividend) record date is July 31, 2022. Cash Dividend Payment Date is August 19, 2022.
Board Change • Jun 04High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Director Hilo Chen is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 27+ 2 more updatesChina Chemical & Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021China Chemical & Pharmaceutical Co., Ltd. at its 2022 annual shareholders meeting held on May 26, 2022, approved cash dividend was TWD 268,272,972 (TWD 0.9 per share) for 2021.
Reported Earnings • May 16First quarter 2022 earnings released: EPS: NT$0.30 (vs NT$0.43 in 1Q 2021)First quarter 2022 results: EPS: NT$0.30 (down from NT$0.43 in 1Q 2021). Revenue: NT$1.98b (flat on 1Q 2021). Net income: NT$88.5m (down 31% from 1Q 2021). Profit margin: 4.5% (down from 6.5% in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Yen Pong Jou was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improved over the past weekAfter last week's 23% share price gain to NT$27.75, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 22x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 65% over the past three years.
Reported Earnings • Apr 01Full year 2021 earnings released: EPS: NT$1.74 (vs NT$1.88 in FY 2020)Full year 2021 results: EPS: NT$1.74 (down from NT$1.88 in FY 2020). Revenue: NT$7.95b (down 2.8% from FY 2020). Net income: NT$517.5m (down 7.2% from FY 2020). Profit margin: 6.5% (down from 6.8% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 10China Chemical & Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year Ended December 31, 2021China Chemical & Pharmaceutical Co., Ltd. announced appropriations of earnings in cash dividends to shareholders is TWD 0.9 for the period ended December 31, 2021.
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS NT$0.43 (vs NT$0.40 in 3Q 2020)The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: NT$1.91b (down 5.4% from 3Q 2020). Net income: NT$128.8m (up 9.7% from 3Q 2020). Profit margin: 6.7% (up from 5.8% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 13Second quarter 2021 earnings released: EPS NT$0.35 (vs NT$0.78 in 2Q 2020)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: NT$2.04b (up 6.4% from 2Q 2020). Net income: NT$105.1m (down 55% from 2Q 2020). Profit margin: 5.2% (down from 12% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Jul 16Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 23 July 2021. Payment date: 20 August 2021. Trailing yield: 4.0%. Lower than top quartile of Taiwanese dividend payers (5.0%). Higher than average of industry peers (2.2%).
Reported Earnings • May 15First quarter 2021 earnings released: EPS NT$0.43 (vs NT$0.38 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: NT$1.99b (down 4.5% from 1Q 2020). Net income: NT$128.6m (up 15% from 1Q 2020). Profit margin: 6.5% (up from 5.4% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
分析記事 • Apr 25Here's Why We Think China Chemical & Pharmaceutical (TPE:1701) Is Well Worth WatchingLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
分析記事 • Apr 07We Think China Chemical & Pharmaceutical (TPE:1701) Can Stay On Top Of Its DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Mar 31Full year 2020 earnings released: EPS NT$1.88 (vs NT$1.29 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: NT$8.18b (up 2.7% from FY 2019). Net income: NT$557.4m (up 45% from FY 2019). Profit margin: 6.8% (up from 4.8% in FY 2019). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 17The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 34% And Shareholders Are Holding OnOn average, over time, stock markets tend to rise higher. This makes investing attractive. But not every stock you buy...
分析記事 • Feb 24China Chemical & Pharmaceutical Co., Ltd.'s (TPE:1701) Stock Has Shown A Decent Performance: Have Financials A Role To Play?Most readers would already know that China Chemical & Pharmaceutical's (TPE:1701) stock increased by 2.7% over the past...
分析記事 • Jan 27Is China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) A Good Fit For Your Dividend Portfolio?Is China Chemical & Pharmaceutical Co., Ltd. ( TPE:1701 ) a good dividend stock? How can we tell? Dividend paying...
Is New 90 Day High Low • Jan 15New 90-day low: NT$22.50The company is down 1.0% from its price of NT$22.65 on 16 October 2020. The Taiwanese market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 19% over the same period.
分析記事 • Jan 06Does China Chemical & Pharmaceutical (TPE:1701) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Dec 23New 90-day high: NT$23.80The company is up 1.0% from its price of NT$23.50 on 24 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 12% over the same period.
分析記事 • Dec 16The China Chemical & Pharmaceutical (TPE:1701) Share Price Is Up 22% And Shareholders Are Holding OnBuying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are...
分析記事 • Nov 26China Chemical & Pharmaceutical Co., Ltd. (TPE:1701) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?With its stock down 3.7% over the past three months, it is easy to disregard China Chemical & Pharmaceutical...
Reported Earnings • Nov 14Third quarter 2020 earnings released: EPS NT$0.39The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$2.02b (up 2.8% from 3Q 2019). Net income: NT$117.5m (up 20% from 3Q 2019). Profit margin: 5.8% (up from 5.0% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 10China Chemical & Pharmaceutical Co., Ltd. Announces Chow,Dah-Jen as Member of Compensation CommitteeChina Chemical & Pharmaceutical Co., Ltd. announced new appointment Member of Compensation Committee, effective November 9, 2020. Name and resume of the new position holder: CHOW,DAH-JEN /AmTRAN Technology’s Independent Director.
お知らせ • Nov 06+ 1 more updateChina Chemical & Pharmaceutical Co., Ltd. Announces Executive ChangesChina Chemical & Pharmaceutical Co., Ltd. announced the Name and resume of the previous position holder: Wang, Hsun-Sheng/CCPC of chairperson. Name and resume of the new position holder: Wang Hsieh Yi-Chen/Ma Jia De Enterprise Co., Ltd. of chairperson. These Changes are effective from November 05, 2020.
